Literature DB >> 27102846

The case for eteplirsen: Paving the way for precision medicine.

M Carrie Miceli1, Stanley F Nelson2.   

Abstract

Mesh:

Substances:

Year:  2016        PMID: 27102846     DOI: 10.1016/j.ymgme.2016.04.001

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


× No keyword cloud information.
  5 in total

Review 1.  Eteplirsen: First Global Approval.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

2.  2'-O-(N-(Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained Activity.

Authors:  Dmytro Honcharenko; Cristina S J Rocha; Karin E Lundin; Jyotirmoy Maity; Stefan Milton; Ulf Tedebark; Merita Murtola; Malgorzata Honcharenko; Andis Slaitas; C I Edvard Smith; Rula Zain; Roger Strömberg
Journal:  Nucleic Acid Ther       Date:  2022-03-02       Impact factor: 4.244

3.  Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.

Authors:  Suxiang Chen; Bao T Le; Madhuri Chakravarthy; Tamer R Kosbar; Rakesh N Veedu
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

4.  Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro.

Authors:  Bao T Le; Abbie M Adams; Susan Fletcher; Stephen D Wilton; Rakesh N Veedu
Journal:  Mol Ther Nucleic Acids       Date:  2017-09-12

5.  Dystrophin Dp71ab is monoclonally expressed in human satellite cells and enhances proliferation of myoblast cells.

Authors:  Manal Farea; Abdul Qawee Mahyoob Rani; Kazuhiro Maeta; Hisahide Nishio; Masafumi Matsuo
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.